Literature DB >> 32144459

Role of baseline volumetric functional MRI in predicting histopathologic grade and patients' survival in hepatocellular carcinoma.

Sanaz Ameli1, Mohammadreza Shaghaghi1, Mounes Aliyari Ghasabeh1, Pallavi Pandey1, Bita Hazhirkarzar1, Maryam Ghadimi1, Roya Rezvani Habibabadi1, Pegah Khoshpouri1, Ankur Pandey1, Robert A Anders1, Ihab R Kamel2,3.   

Abstract

OBJECTIVES: We aimed to evaluate the role of volumetric ADC (vADC) and volumetric venous enhancement (vVE) in predicting the grade of tumor differentiation in hepatocellular carcinoma (HCC).
METHODS: The study population included 136 HCC patients (188 lesions) who had baseline MR imaging and histopathological report. Measurements of vVE and vADC were performed on baseline MRI. Tumors were histologically classified into low-grade and high-grade groups. The parameters between the two groups were compared using Mann-Whitney U and chi-square tests for continuous and categorical parameters, respectively. Area under receiver operating characteristic (AUROC) was calculated to investigate the accuracy of vADC and vVE. Logistic regression and multivariable Cox regression were used to unveil the potential parameters associated with high-grade HCC and patient's survival, respectively.
RESULTS: Lesions with higher vADC values and a higher absolute vADC skewness were more likely to be high grade on histopathology assessment (p = 0.001 and p = 0.0291, respectively). Also, vVE showed a trend to be higher in low-grade lesions (p = 0.079). Adjusted multivariable model including vADC, vVE, and vADC skewness could strongly predict HCC degree of differentiation (AUROC = 83%). Additionally, a higher Child-Pugh score (HR = 2.39 [p = 0.02] for score 2 and HR = 3.47 [p = 0.001] for score 3), vADC skewness (HR = 1.52, p = 0.02; per increments in skewness), and tumor volume (HR = 1.1, p = 0.001; per 100 cm3 increments) showed the highest association with patients' survival.
CONCLUSIONS: vADC and vVE have the potential to accurately predict HCC differentiation. Additionally, some imaging features in combination with patients' clinical characteristics can predict patient survival. KEY POINTS: • Volumetric functional MRI metrics can be considered as non-invasive measures for determining tumor histopathology in HCC. • Estimating patient survival based on clinical and imaging parameters can be used for modifying management approach and preventing unnecessary adverse events.

Entities:  

Keywords:  Hepatocellular carcinoma; Magnetic resonance imaging; Survival analysis

Mesh:

Year:  2020        PMID: 32144459     DOI: 10.1007/s00330-020-06742-8

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  5 in total

1.  Whole tumor volumetric ADC analysis: relationships with histopathological differentiation of hepatocellular carcinoma.

Authors:  Ferhat Can Piskin; Huseyin Tugsan Balli; Kivilcim Eren Erdoğan; Sinan Sozutok; Kairgeldy Aikimbaev
Journal:  Abdom Radiol (NY)       Date:  2021-08-20

2.  Noninvasively predict the micro-vascular invasion and histopathological grade of hepatocellular carcinoma with CT-derived radiomics.

Authors:  Xu Tong; Jing Li
Journal:  Eur J Radiol Open       Date:  2022-05-16

Review 3.  Current updates in machine learning in the prediction of therapeutic outcome of hepatocellular carcinoma: what should we know?

Authors:  Zhi-Min Zou; De-Hua Chang; Hui Liu; Yu-Dong Xiao
Journal:  Insights Imaging       Date:  2021-03-06

4.  Initial Incomplete Thermal Ablation Is Associated With a High Risk of Tumor Progression in Patients With Hepatocellular Carcinoma.

Authors:  Jie Tan; Tian Tang; Wei Zhao; Zi-Shu Zhang; Yu-Dong Xiao
Journal:  Front Oncol       Date:  2021-10-18       Impact factor: 6.244

5.  Clinical and imaging features preoperative evaluation of histological grade and microvascular infiltration of hepatocellular carcinoma.

Authors:  Ling Zhang; Jiong-Bin Lin; Ming Jia; Chen-Cai Zhang; Rong Xu; Le Guo; Xiao-Jia Lin; Quan-Shi Wang
Journal:  BMC Gastroenterol       Date:  2022-08-01       Impact factor: 2.847

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.